25,341 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Purchased by Avanza Fonder AB

Avanza Fonder AB bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 25,341 shares of the company's stock, valued at approximately $866,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Farther Finance Advisors LLC grew its stake in shares of CRISPR Therapeutics by 46.7% during the first quarter. Farther Finance Advisors LLC now owns 5,626 shares of the company's stock worth $186,000 after buying an additional 1,792 shares during the last quarter. NBC Securities Inc. grew its stake in shares of CRISPR Therapeutics by 156,300.0% during the first quarter. NBC Securities Inc. now owns 1,564 shares of the company's stock worth $53,000 after buying an additional 1,563 shares during the last quarter. Green Alpha Advisors LLC grew its stake in shares of CRISPR Therapeutics by 132.9% during the first quarter. Green Alpha Advisors LLC now owns 57,361 shares of the company's stock worth $1,952,000 after buying an additional 32,732 shares during the last quarter. 180 Wealth Advisors LLC grew its stake in shares of CRISPR Therapeutics by 22.9% during the first quarter. 180 Wealth Advisors LLC now owns 6,349 shares of the company's stock worth $216,000 after buying an additional 1,182 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of CRISPR Therapeutics by 8,146.2% during the first quarter. GAMMA Investing LLC now owns 4,288 shares of the company's stock worth $146,000 after buying an additional 4,236 shares during the last quarter. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP traded up $0.08 during trading on Friday, hitting $41.36. 2,016,735 shares of the company traded hands, compared to its average volume of 1,753,450. The business's fifty day moving average is $37.75 and its 200 day moving average is $40.82. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $63.68. The firm has a market capitalization of $3.57 billion, a price-to-earnings ratio of -9.46 and a beta of 1.75.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. During the same quarter last year, the business posted ($1.43) EPS. CRISPR Therapeutics's quarterly revenue was up 71.6% on a year-over-year basis. On average, analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Activity

In other news, insider Naimish Patel sold 3,932 shares of the company's stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the transaction, the insider now owns 6,068 shares in the company, valued at approximately $218,083.92. This represents a 39.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.30% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, May 20th. The Goldman Sachs Group reduced their price objective on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Cantor Fitzgerald reissued a "neutral" rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, JMP Securities reissued a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, May 21st. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $71.75.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.